Angiotensin II receptors and functional correlates.

  title={Angiotensin II receptors and functional correlates.},
  author={Pieter B.M.W.M. Timmermans and Pamela A. Benfield and Andrew T. Chiu and William F. Herblin and Pancras C Wong and Ronald D. Smith},
  journal={American journal of hypertension},
  volume={5 12 Pt 2},
Angiotensin II (ANG II) is the primary mediator of the renin-angiotensin system, which has an important functional role in cardiovascular homeostasis. The angiotensin receptor and its functional correlates have been redefined by the cloning of angiotensin receptors and the discovery and widespread study of specific nonpeptide ANG II-receptor antagonists losartan (AT1 selective) and PD123177 (AT2 selective). With these antagonists, it has been possible to extend the concept of ANG II-receptor… 
Angiotensin receptors: distribution, signalling and function.
Recent advances in the understanding of angiotensin II receptors are discussed, in particular, their distribution, signalling and function.
Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.
A-II receptor antagonism appears to be as effective as ACE inhibition in the treatment of hypertension and other pathologic processes that involve the RAS and may offer an alternative to those patients who cannot tolerate ACE inhibitors because of their side effects.
Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy
Clinical studies confirm the AII antagonist action ofLosartan and suggest that losartan will be effective in the treatment of essential HTN, and the utility of AII antagonism may extend beyond that of HTN and CHF, as suggested by the potential usefulness of angiotensin‐converting enzyme inhibition.
Medicinal Chemistry of Angiotensin II Antagonists
The renin—angiotensin system (RAS) has been demonstrated to be a key element in blood pressure regulation and sodium balance.1 The therapeutic and commercial success of angiotensin-converting enzyme
Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications
The present review focuses on the novel components and pathways of the RAS with particular reference to their potential contribution towards the pathophysiology of liver disease.
AT1-receptor blockers: differences that matter
  • A. Gradman
  • Medicine
    Journal of Human Hypertension
  • 2002
Pharmacological differences between AT1-receptor blockers are reflected in clinically important differences in maximal antihypertensive effect, response rate, and duration of action.
Angiotensin-Converting Enzyme Inhibitors an Angiotensin II-Receptor Antagonists
The inhibition of the RAAS at the level of the transmitter-receptor interaction seems to be a logical development because nonpeptide (ie, orally active) angiotensin II (AT) receptor antagonists are available and this concept can be proven.
Overview of angiotensin II-receptor antagonists.
A brief overview of the pharmacology and clinical use of angiotensin II-receptor blockers with some comparisons to ACE inhibitors is provided.
Angiotensin II receptor blockade and ventricular remodelling
By blocking at the receptor level, Ang II receptor blockers (ARBs) provide an alternative and more direct approach to inhibiting the effects of Ang II; however, data relating to their effects upon ventricular remodelling are less convincing.
Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling
The objective of this review is to examine the role of neuronal angiotensin II (Ang II) receptors in vitro and putative cross-talk pathways between AT1 and AT2 receptors will be discussed.